Compare Digital Realty Trust, Inc. (DLR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs TG Therapeutics Inc — how do they compare? Digital Realty Trust, Inc. trades at $197.15 (market cap $70.61B), while TG Therapeutics Inc trades at $49.59 (market cap $7.64B). The key difference: Digital Realty Trust, Inc. is far larger — about 9.2× TG Therapeutics Inc's market cap, and Digital Realty Trust, Inc. pays a 2.56% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DLR | TGTX | |
|---|---|---|
Market Cap | $70.61B | $7.64B |
Sector | Real Estate | Health |
52-Week High | $203.91 | $59.06 |
52-Week Low | $147.93 | $26.94 |
Enterprise Value | $89.32B | $7.84B |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLR trades at $197.02, up 2.99% today, near its consensus price target low of $197.00. The stock shows bullish technical signals with strong moving averages, while fundamentals reveal high valuation multiples (P/E 241.53, P/S 25.08) offset by robust revenue growth to $6.11B in 2025 and a net income margin of 11.8%. Recent Q2 2026 earnings beat expectations with EPS of $1.21 versus $0.48 expected, driven by record leasing activity and raised full-year guidance.
Outlook remains positive due to AI-driven data center demand, but risks include elevated debt levels and cyclical earnings. Analysts are bullish with a $216.56 average target, though premium valuation requires monitoring execution against growth expectations.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
